Search - tctmd.com

Displaying 121 - 140 of 179

Sort: Relevancy | Date

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

Yael L. Maxwell

August 14, 2019

News Conference News SCCT 2019

Chest Pain Rule-Out? For Two ED Scores, It’s a Draw

Yael L. Maxwell

July 19, 2019

News Daily News

Microvascular Disease Quadruples Risk of Leg Amputation

L.A. McKeown

July 08, 2019

News Daily News

Vitamin D for CV Risk? Think Twice, Meta-analysis Confirms

Marcus A. Banks

June 21, 2019

News Conference News SCAI 2019

Antithrombotic Use, Risk Perception, Varies Widely for PCI Patients With A-fib

Yael L. Maxwell

May 24, 2019

News Daily News

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

Yael L. Maxwell

May 15, 2019

News Daily News

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Yael L. Maxwell

April 22, 2019

News Daily News

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

Yael L. Maxwell

April 18, 2019

News Daily News

Initiative Helps Low-Resource Chinese Hospitals Provide Better ACS Care

L.A. McKeown

April 17, 2019

News Conference News ACC 2019

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Yael L. Maxwell

March 22, 2019

News Daily News

Abnormal Coronary Reactivity in Women Portends Added CV, Death Risk in the Next Decade

Caitlin E. Cox

February 13, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2018

Shelley Wood

November 30, 2018

News Conference News AHA 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

Todd Neale

November 10, 2018

News Daily News

Final Phase III Bempedoic Acid Trial Proves Positive for LDL-Lowering

Shelley Wood

October 29, 2018

News Daily News

Vulnerable Plaque Components Seen on IVUS Not Linked With MACE, Two New Studies Show

Michael O'Riordan

October 17, 2018

News Daily News

Silent Infarcts Have Similar Mortality Over 10 Years as Clinically Recognized MI

Yael L. Maxwell

October 10, 2018

News Daily News

Varenicline Boosts Long-term Quit Rate in Post-ACS Smokers: EVITA

Caitlin E. Cox

March 26, 2018

News Conference News ACC 2018

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

Michael O'Riordan

March 14, 2018

News Conference News ACC 2018

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Michael O'Riordan

March 10, 2018

Advertisement

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

Chest Pain Rule-Out? For Two ED Scores, It’s a Draw

Microvascular Disease Quadruples Risk of Leg Amputation

Vitamin D for CV Risk? Think Twice, Meta-analysis Confirms

Antithrombotic Use, Risk Perception, Varies Widely for PCI Patients With A-fib

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

Initiative Helps Low-Resource Chinese Hospitals Provide Better ACS Care

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Abnormal Coronary Reactivity in Women Portends Added CV, Death Risk in the Next Decade

TCTMD’s Top 10 Most Popular Stories for November 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

Final Phase III Bempedoic Acid Trial Proves Positive for LDL-Lowering

Vulnerable Plaque Components Seen on IVUS Not Linked With MACE, Two New Studies Show

Silent Infarcts Have Similar Mortality Over 10 Years as Clinically Recognized MI

Varenicline Boosts Long-term Quit Rate in Post-ACS Smokers: EVITA

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content